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Abstract
Background: The oncologic safety of allogeneic blood transfusion in ovarian cancer patients is unknow. We sought
to determine the prevalence and oncologic safety of perioperative allogeneic blood transfusion during interval
cytoreduction surgery among women receiving neoadjuvant chemotherapy for ovarian cancer.
Methods: We utilized retrospective chart review to identify a cohort of patients undergoing interval cytoreduction at a
large academic tertiary referral center. We compared outcomes in patients who were exposed to perioperative blood
transfusion compared with patients who were not exposed. Our primary endpoint was progression free survival; our
secondary endpoint was overall survival. Baseline clinical characteristics were collected for patients in each group.
Results: Sixty-six women were included in the final cohort of women undergoing interval cytoreductive surgery after
NACT. A total of 51 women (77%) were exposed to allogeneic perioperative pRBC transfusion. Fifteen women (23%)
were not exposed to transfusion. The baseline characteristics were generally well matched. Women who were not
exposed to a perioperative blood transfusion were more likely to have a normalized CA125 prior to undergoing
cytoreductive surgery. Preoperative hemoglobin concentration was lower in the transfusion group (10.5 g/dLvs 11.5 g/
dL, p < 0.009). Perioperative transfusion was not associated with a significant difference in progression free survival
(PFS = 7.6 months for transfused, 9.4 months for not transfused; log-rank test p = 0.4617). Similarly, there was no
observed difference between groups for overall survival (OS = 23.6 months for transfused, 22.5 months for not
transfused; log-rank test p = 0.1723).
Conclusions: Women undergoing neoadjuvant chemotherapy for ovarian cancer are at high risk of exposure to blood
transfusion at the time of interval cytoreductive surgery. Future studies will continue to evaluate the safety and impact
of transfusion on ovarian cancer survival in this at risk population.
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Background
Blood transfusion has been scrutinized in intensive care
and trauma settings, as it is consistently associated with
worse outcomes [1, 2]. In cancer patients, perioperative
blood transfusions have been shown to worsen survival
in colorectal, breast and other malignancies [3–7]. These
findings have been inconsistently replicated in patients
with ovarian cancer [8, 9] but limited research in this
area has been published. The treatment paradigm for pa-
tients with advanced ovarian cancer has shifted in the
last eight years. The use of neoadjuvant chemotherapy
(NACT) as an alternative to upfront debulking surgery
has gained widespread acceptance after two randomized
controlled studies showed equivalent survival between
these treatment paradigms [10, 11]. We reasoned that
patients undergoing going interval cytoreductive surgery
after NACT would be uniquely at risk for perioperative
anemia secondary to myelosuppressive chemotherapy.
Consequently we anticipated a high prevalence of peri-
operative blood transfusion in this growing patient
population. However, the impact of perioperative blood
transfusion on progression-free survival (PFS) and over-
all survival (OS) remains an unanswered question. We
identified a retrospective cohort of patients with ovarian
cancer undergoing interval cytoreduction after NACT at
our institution over a 3 year period to determine the
prevalence of perioperative blood transfusion and ex-
plore the impact on OS and PFS.
Methods
We utilized Electronic Health Records (EHR) from
women undergoing treatment of ovarian cancer at the
University of Wisconsin Hospital from January 1 2010 to
December 31 2013. We selected our data collection win-
dow to coincide with the increased uptake of NACT
after the publication of EORTC 55971 trial in 2010. A
search of patient data from prior to 2010 showed an
overall low rate of NACT at our institution. We chose to
terminate data collection in 2013 to provide opportunity
for maturation of survival data. We utilized ICD9 code
183 and CPT codes 58943 and 58950-58956 to identify
all women undergoing surgical treatment for ovarian
cancer. We then manually interrogated records to iden-
tify women who had previously received chemotherapy
prior to surgical management. There are no well-defined
criteria for peri-operative blood transfusion described in
the literature. We chose to define the exposure of inter-
est, perioperative allogeneic blood transfusion, as any
women who received allogeneic packed red blood cells
during their index hospitalization for interval cytoreduc-
tion surgery. We surmised that there is great variability
in the timing and utilization of blood products depend-
ing on patient factors and provider preferences. As a re-
sult, we chose this broad definition to be maximally
inclusive of exposures surrounding interval surgery. The
primary outcome of interest was progression-free sur-
vival and the secondary outcome was OS, calculated as
the interval from surgery until recurrence or death, re-
spectively. Recurrence was defined as any clinically sus-
pected recurrence by imaging, exam or biochemical
findings. Demographic data including age and BMI were
obtained, as well as clinical data including pre-treatment
CA125, preoperative CA125, preoperative clinical stage,
chemotherapy regimen, optimal cytoreduction status,
final surgical stage, preoperative hemoglobin and num-
ber of units of packed red blood cells transfused.
Women lost to follow up were censored from survival
analysis. For the primary analysis of PFS and the second-
ary endpoint of OS, the difference in treatment arms
was assessed using Kaplan-Meier (KM) methods and the
log-rank test. Median, ranges, the proportion of subjects
who are progression free in this cohort, hazard ratios
and corresponding 95% confidence intervals (as calcu-
lated using a Cox proportional hazards regression
model) are presented. In addition, differences in the fre-
quency distributions of baseline covariates by transfu-
sion type were compared via Chi-square or Fisher’s
exact test test for categorical variables and a t-test for
continuous variables. Data analysis was performed using
the SAS v9.4 software. The study protocol was submit-
ted to the UW-Madison Institutional Review Board and
granted exemption status.
Results
We identified 273 women who received surgical treatment
of ovarian cancer at the University of Wisconsin between
2010 and 2013. A total of 70 (25%) women underwent
NACT prior to surgical cytoreduction, as compared to
203 (75%) women undergoing primary cytoreduction sur-
gery. Four women undergoing NACT were excluded in
our final analysis; three had primary uterine cancer and
one had primary appendiceal carcinoma. Sixty-six women
were included in the final cohort of women who undergo-
ing interval cytoreductive surgery after NACT (Fig. 1).
The mean age of women included in the study was
69 years old, with a range from 33 to 87. The mean BMI
in our cohort was 28 kg/m2, with a range from 18 to 49.
An overwhelming majority of patients in the cohort had
high grade papillary serous histology (91%). Other histolo-
gies included low grade serous (3%), clear cell (3%), mu-
cinous (1.5%), and endometrioid (1.5%). The mean
pre-treatment CA125 for the overall cohort was
2818 units/mL, with a range from 15 to 30,536 units/mL.
The mean pre-surgery CA125 (last documented value
prior to date of surgery) was 259 units/mL, with a range
from 3 to 6190 units/mL. Of the 66 women included in
the final cohort, 22 patients (33%) had a normal CA125
prior to surgery. Given that residual tumor burden is the
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most important surgical variable for ovarian cancer sur-
vival, we gathered this data on surgical outcome for the
entire cohort. Optimal debulking status was known for all
patients. Seventeen out of 66 (26%) had no visible disease
after surgery. Twelve out of 66 (18%) had cytoreduction to
1–5 mm of visible disease. Twenty-nine of 66 (44%) of pa-
tients had cytoreduction to less than or equal to 1 cm of
visible disease. Eight of 66 (12%) had a suboptimal cytore-
duction. Operative blood loss was also known for all pa-
tients, with a mean intraoperative blood loss of 539 mL
(range 100–2000 mL). Among all patients, the mean pre-
operative hemoglobin concentration was 10.6 g/dL.
The majority of our patients received a
platinum-containing doublet delivered every 3 weeks prior
to surgery. Fifty-five out of 66 (83%) patients received neo-
adjuvant carboplatin and paclitaxel. Six out of 66 (9%) re-
ceived carboplatin, paclitaxel, bevacizumab prior to
surgery. Five out of 66 (8%) of patients received NACT
with some other chemotherapy regimen (four with
carboplatin/taxotere, one with carboplatin/gemcitabine).
Four women received paclitaxel on a weekly (i.e.
dose-dense) schedule. The majority of women in our co-
hort received 3 cycles of neoadjuvant chemotherapy
(66%). Forty-seven patients (71%) had clinical stage III dis-
ease at the beginning of treatment, with 17 (26%) patients
having clinical stage IV disease. One patient had stage I
disease; this patient presented to our facility with
biopsy-proven clear cell cancer and extensive pulmonary
emboli. She was managed medically with anticoagulation
and neoadjuvant carboplatin-paclitaxel. Final surgical
staging confirmed unilateral ovarian disease without
contralateral ovarian involvement; given her preoperative
biopsy she was managed as stage Ic. The median time to
progression among the entire cohort was 7.7 months
(range 0-53 months). The median time to death (overall
survival) was 22.5 months (range 1 to 62.3 months. At the
conclusion of the study, 19 patients were alive, and 45
were deceased. Two patients were lost to follow up with-
out survival data available. Four women were in complete
remission at the conclusion of the study.
The baseline characteristics of women in the transfusion
and non-transfusion groups are shown in Table 1. A total of
51 women (77%) were exposed to allogeneic perioperative
pRBC transfusion. Fifteen women (23%) were not exposed
to transfusion. The mean number of units of packed red
blood cells transfused was 2.98 units. The baseline charac-
teristics were generally well-matched. There was no ob-
served relationship between the number of preoperative
chemotherapy cycles and the likelihood of exposure to blood
transfusion. Women who were not exposed to a periopera-
tive blood transfusion were more likely to have a normalized
CA125 prior to undergoing cytoreductive surgery. (CA125
<35 units/mL, p=0.005). Preoperative hemoglobin concen-
tration was observed to be lower in the group exposed to
blood transfusion (10.5 g/dL vs 11.5 g/dL, p<0.009), and also
observed to have a higher mean operative blood loss (613.7
mL vs 283.3 mL, p=0.004).The results of Kaplan-Meier ana-
lysis of our primary and secondary outcomes of interest are
shown in Figs. 2 and 3. Perioperative transfusion was not as-
sociated with a significant difference in progression free
Women undergoing surgery for ovarian
cancer
Women receiving neoadjuvant chemotherapy
(n=70)
Inclusion in final cohort
(n=66)
Not 
Transfused
Transfused
(n=51)
Excluded due to 
primary cytoreduction 
surgery 
n=203
Excluded due to non-
ovarian malignancy
n=4
Fig. 1 Study population: women treated for ovarian cancer at University of Wisconsin between 2010 and 2013
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Table 1 Baseline characteristics
Variable Perioperative Transfusion: Yes (N=51)
Mean (SD)
Perioperative Transfusion: No (N=15)
Mean (SD)
P-value
Age 69.0 (11.46) 71.1 (9.60) 0.5278
BMI 28.0 (7.31) 26.7 (5.68) 0.5183
Histology:
High grade pap serous 46 14 0.299
Low grade 2 0
Mucinous 1 0
Clear cell 2 0
Endometrioid 0 1
Pre-treatment CA125 3013.4 (5833.6) 2156.9 (2897.4) 0.5863
Pre-operative CA125 198.8 (401.6) 462.8 (1585.2) 0.2822
Normal Pre-op:
Yes 11 9 0.005
No 39 6
Delta CA125 2867.5 (5702.6) 1694.2 (1592.9) 0.4361
Pre-op Clinical Stage:
Stage 3 36 11 0.992
Stage 4 13 4
Pre-op Chemo: 0.907
Carboplatin/Paclitaxel 41 13
Carbo/taxol/bevacizumab 5 1
Other 4 1
Dose-dense Taxol: 0.258
Yes 4 0
No 46 15
Pre-op Chemotherapy cycle # 0.21
3 or less 37 8
< 3 14 7
Optimal Cytoreduction: 0.812
No visible 12 (23.5%) 5 (33.3%)
1-5mm 9 (17.6%) 3 (20%)
≤1cm 22 (43.1%) 6 (40%)
Suboptimal 7 (13.7%) 1 (6.7%)
Final Stage: 0.646
Ic 1
IIIc 38 10
IVa 8 4
IVb 4 1
Pre-op HgB (g/dL) 10.5 (0.16) 11.5 (0.44) 0.0091
Operative blood loss (mL) 613.7 (421 ) 283.3 (144.7 ) 0.004
Number of Units Transfused
zero units 0 15
1-3 units 36 0
4-7 units 15 0
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survival. Among women exposed to transfusion a median
PFS of 7.6 months was observed, as compared to a median
PFS of 9.4 months among women not exposed to transfu-
sion (log-rank test p= 0.4617). Similarly, there was no ob-
served difference between groups for overall survival
(23.6 months in transfused group, 22.5 months in not trans-
fused group; log-rank test p = 0.1723). We hypothesized that
an inverse dose relationship might exist between the num-
ber of units transfused and survival. Using a Cox propor-
tional hazards model, we found no significant association
between number of units transfused and OS (HR= 1.06, CI:
0.92–1.23) nor PFS (HR= 1.14, CI: 0.87–1.50). Previous
studies have demonstrated a pre-surgery normal CA125 as a
positive prognostic variable. In our cohort a normal CA125
trended towards an observed increase in PFS, however there
was no statistical difference in OS.
Discussion
Collectively, our experience from a single academic ter-
tiary referral institution demonstrates a high utilization
of perioperative pRBC transfusion at the time of surgery
among women undergoing NACT for ovarian cancer.
To our knowledge, this is the first study to report the
prevalence of blood transfusion among women undergo-
ing NACT for ovarian cancer in North America. Specif-
ically, our cohort was collected over a time interval
during which an increasing number of women are being
treated with primary chemotherapy and interval cytore-
duction surgery. Patients receiving blood product trans-
fusion face risks including infectious, allergic reactions,
non-allergic immune reactions, and volume overload.
Data from other patient populations suggests that allo-
geneic blood product transfusion may be associated with
poorer oncologic outcomes [3–7]. This has been demon-
strated in advanced ovarian cancer patients undergoing
primary cytoreduction surgery for stage III disease where
transfusion was associated with a shortened median time
to progression or survival of 6 months and 22 months,
respectively [8]. Our cohort specifically identified
women undergoing surgery after NACT for ovarian can-
cer because we hypothesized that this patient population
is at increased risk of chronic anemia secondary to bone
marrow suppression from carboplatin and paclitaxel.
Interestingly, we observed no relationship between
Table 1 Baseline characteristics (Continued)
Variable Perioperative Transfusion: Yes (N=51)
Mean (SD)
Perioperative Transfusion: No (N=15)
Mean (SD)
P-value
Days to death 662.9 (65.7) 865.8 (177.6) 0.1959
Alive: 0.918
Yes 14 4
No 35 10
Median time to death was compared between patients who received perioperative blood transfusion (red line) versus those who did not (blue line).
OS = 23.6 months for transfusion group; OS = 22.5 months for no transfusion group. Data were analyzed using the log-rank test
log-rank: P=0.4617
0.
00
0.
25
0.
50
0.
75
1.
00
0 10 20 30 40 50
Time (months)
Transfusion = No Transfusion = Yes
Progression-Free Survival
Fig. 2 Kaplan-Meier Analysis of patients undergoing interval cytoreduction after NACT. Median time to progression was compared between patients
who received perioperative blood transfusion (red line) versus those who did not (blue line). PFS = 7.6 months for transfusion group; PFS = 9.44 no
transfusion group. Data were analyzed using the log-rank test
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number of preoperative chemotherapy cycles and likeli-
hood of exposure to perioperative blood transfusion.
Nevertheless, in comparison to the patients included in
the study of De Oliveira et al. we observed a lower pre-
operative hemoglobin level in our cohort (10.5 g/dL vs
11.2 g/dL) [8]. Congruently, we observed a higher rate of
transfusion (77% vs 56%). We did not detect a difference
in progression-free survival between women exposed to
blood transfusion compared with women who were un-
exposed. Similarly, for the secondary outcome of overall
survival, we did not observe a significant difference
associated with exposure to blood transfusion. Two
variables were significantly associated with exposure to
transfusion: preoperative hemoglobin level and operative
blood loss. While these are intuitive risk factors for
transfusion, it is unlikely that operative blood loss can be
reliably modified in patients undergoing cytoreductive
surgery. As a result, correction of preoperative anemia
may present an opportunity for future efforts geared to-
wards reducing peri-operative blood transfusion.
Our data warrants contextualization with key articles
from Vergote et al... and the CHORUS trial that investi-
gated the non-inferiority of NACT with interval cytore-
duction in ovarian cancer patients [10, 11]. For our
cohort, the overall median survival was 22.5 months. In
comparison, Vergote et al.. observed a 30-month median
overall survival in the NACT group. The CHORUS trial
reported median overall survival of 24 months. It may
be that the observed differences represent a relatively
higher burden of disease in our patient population. Sev-
eral lines of evidence support this: first, whereas Vergote
et al.. observed stage IV disease in 23% of their patients,
we observed stage IV disease in roughly 26% of our
cohort. A similar rate of Stage IV disease was reported
in the CHORUS trial (25%). Second, Vergote et al ob-
served a pretreatment CA125 of ~ 1100 units/mL. In
contrast, we observed a pretreatment CA125 that was
nearly three times greater (~ 2800 units/mL). Though it
was collected, the authors of the CHORUS trial did not
publish the pretreatment CA125 levels in their study. In
addition, Kessous et al recently published their experi-
ence from a retrospective cohort of North American
women undergoing treatment for ovarian cancer and ob-
served that women who received NACT had a roughly
3-fold higher CA125 level prior to treatment [12]. Col-
lectively, these differences give support to the general
practice patterns in the United States and North Amer-
ica that NACT is often reserved for patients with signifi-
cant medical co-morbidities and/or a high burden of
disease that would limit an optimal surgical effort. An
important comparison between our cohort and the
above mentioned trials is the apparent difference in the
rates of blood transfusion between our U.S. cohort and
the published European trials. While neither the Vergote
study nor the CHORUS trial report specifically on blood
product utilization, they do report grade 3 and 4
hemorrhage using Common Terminology Criteria for
Adverse Events (CTCAE). Using these criteria, grade 3/4
hemorrhage would include all women undergoing blood
transfusion of at least 2 units of packed red blood cells.
The rate of grade 3 or 4 hemorrhage events among
women undergoing NACT in these European trials
ranged from 3 to 7%. In stark contrast, 77% of women
undergoing NACT in our cohort received a blood trans-
fusion. While these two outcomes are not directly com-
parable, our data suggests that ovarian cancer patients
log-rank: P=0.1723
0.
00
0.
25
0.
50
0.
75
1.
00
0 20 40 60
Time (months)
Transfusion = No Transfusion = Yes
Overall Survival
Fig. 3 Kaplan-Meier Analysis of patients undergoing interval cytoreduction after NACT
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who are treated with primary chemotherapy in North
America represent a qualitatively different patient popu-
lation that is at increased risk of exposure to allogeneic
blood transfusion.
Our study has several shortcomings that limit its gen-
eral applicability. Our design was retrospective and indi-
cations for transfusion are not standardized among
providers. Moreover,
at our institution patients are often initiated on NACT
by referring medical oncologists prior to a consultation
with a gynecologic oncologist. This creates multiple op-
portunities for unmeasured variables to alter our results
and conclusions. Moreover, the small number of subjects
likely limited our ability to observe differences between
groups that may exist. Future studies incorporating data
from multiple institutions and/or collected prospectively
with standardized procedures would address some of
these limitations.
Conclusion
In conclusion, we found a high rate of perioperative allo-
geneic blood transfusion in women undergoing interval
cytoreductive surgery for ovarian cancer after NACT. Lar-
ger and prospective trials will help further evaluate the re-
lationship between blood transfusion and oncologic
outcomes among women receiving NACT. We identified
preoperative anemia and operative blood loss as risk fac-
tors for exposure to peri-operative transfusion. Future
studies to evaluate the feasibility of correcting preopera-
tive anemia while women are undergoing NACT may help
reduce blood product utilization in this at-risk population.
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